The General Court of the European Union has dismissed an Anglo-American orphan drug company’s bid to block the European Medicines Agency from releasing a clinical study report for one of its treatments, finding the information wasn’t protected by EU rules on access to documents.

An English judge has asked lawyers for the European Medicines Agency and the Canary Wharf Group to make submissions that will help him “go back in time” to 2011, to better assess the predictability of Brexit at the time the agency signed its London lease.

The EU General Court has found that the European Commission acted legally when it rejected a complaint alleging anticompetitive dual pricing in the pharmaceutical market, despite it misinterpreting a previous judgment on the enforcer’s 2001 decision.

The High Court in London has refused to grant drugmakers Bayer and Novartis’ request for a judicial review of a decision by 12 NHS clinical commissioning groups (CCGs) in the north of England to offer Roche’s Avastin as a preferred treatment option for a degenerative sight condition, rather than their more expensive alternatives.

DLA Piper’s US life sciences group has hired two IP partners from Hogan Lovells in New York and a litigator from Vinson & Elkins in Texas.